JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morita, T.
Right arrow Articles by Kourembanas, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morita, T.
Right arrow Articles by Kourembanas, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 272, Number 52, Issue of December 26, 1997 pp. 32804-32809

Carbon Monoxide Controls the Proliferation of Hypoxic Vascular Smooth Muscle Cells*

(Received for publication, August 25, 1997, and in revised form, October 16, 1997)

Toshisuke Morita Dagger , S. Alex Mitsialis §, Hideo Koike Dagger , Yuxiang Liu Dagger and Stella Kourembanas Dagger

From the Dagger  Joint Program in Neonatology, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115 and the § Department of Medicine, Boston University Medical Center, Boston, Massachusetts 02118

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Excess vascular smooth muscle cell (VSMC) proliferation and contractility are key events in the pathophysiology of vascular disorders induced by hypoxia. We have recently reported that carbon monoxide (CO), produced by VSMC under conditions of hypoxia, can be a modulator of cGMP levels in both endothelial and smooth muscle cells. In this respect, some of the physiologic effects of CO in the vasculature parallel those of nitric oxide (NO), a well characterized regulator of vascular tone. We report here that under hypoxia, VSMC-derived CO is an important regulator of VSMC proliferation. Inhibiting CO formation or scavenging CO with hemoglobin increased VSMC proliferation in response to serum or to mitogens such as endothelin, whereas increasing CO production or exposing cells to exogenous CO lead to a markedly attenuated growth response. The effects of CO on VSMC proliferation correlated with changes in E2F-1 expression, the prototype member of a family of transcription factors that participate in the control of cell cycle progression. CO significantly suppressed E2F-1 expression, whereas, removal of CO from the cultures with hemoglobin lead to increased E2F-1 gene transcription, mRNA, and protein production as well as mRNA levels of c-myc, a target gene of E2F-1. Moreover, the actions of CO were mediated by the second messenger molecule, cGMP. Limiting VSMC growth by increasing the release of CO may represent a key event in the body's compensatory responses to hypoxia.


INTRODUCTION

Hypoxia has profound effects on blood vessel tone and cell growth. The cellular responses to hypoxia involve changes in DNA-protein interactions leading to altered gene expression (1, 2) and, ultimately, to cell proliferation and contractility. As more is learned about these responses to hypoxia, it has become evident that they involve complex cell-cell interactions mediated by both endothelial and smooth muscle cell-derived signals.

We have shown that under hypoxia, vascular smooth muscle cells (VSMC)1 up-regulate the expression of the heme oxygenase-1 (HO-1) gene, resulting in increased production of carbon monoxide (CO) (3). Cook et al. (4) using a sensitive gas chromatographic method, also reported HO-dependent CO production in the rat aorta, suggesting a physiological role for CO in VSMC relaxation. HO-1 is the inducible isoform of HO, which catalyzes the conversion of heme to biliverdin and CO (5, 6). The regulation of HO-1 by hypoxia hence affects both heme homeostasis in the body and CO levels in VSMC. CO has similar properties to the well known gas molecule, nitric oxide (NO). Both CO and NO activate guanylyl cyclase activity, thus raising intracellular cGMP levels. In addition to being a potent vasodilator, NO has been reported to inhibit the proliferation of tumor cells, (7) as well as cultured rat VSMC (8). Very little is known about the biology of CO. CO produced from the activity of the constitutive enzyme HO-2 has been shown to be important in neuronal signal transduction (9) and may have endothelial-derived relaxing activity (10). We have reported that CO produced from the activity of HO-1 in hypoxic VSMC may play a physiologic role in the vasculature by regulating the production of the growth factors, endothelin-1 (ET-1), and platelet-derived growth factor-B (PDGF-B), thus indirectly regulating VSMC proliferation (11).

Hypoxia induces the expression of genes for growth factors and genes encoding glycolytic enzymes at least partially through the action of hypoxia-inducible factor-1 (1, 12-14). Hypoxia-inducible factor-1 is a basic-loop-helix-Per-Arnt/AhR-Sim heterodimeric transcription factor that is itself regulated by hypoxia (2). The mechanisms by which hypoxia regulates cell cycle-related processes, however, are poorly understood. Little is known about the downstream targets of growth control pathways that are activated by a hypoxic environment. The E2F family of transcription factors has been implicated in the regulation of genes essential for orderly cell cycle progression, such as c-myc, cyclins, and DNA polymerase-alpha (15, 16). E2F-1 was the first member of this family to be characterized and was shown to be critical for the G1/S phase transition (17, 18). E2F-5, on the other hand, the latest member of this family to be cloned (19-21) has a pattern of expression throughout the cell cycle that is distinct from that of E2F-1 and may play an active role in the G0/G1 transition and cell differentiation (19, 21). In this study, we examined the pattern of expression of these two genes in VSMC under conditions of hypoxia and correlated them with cell growth. Given that CO production is dramatically increased by hypoxia, whereas NO production is suppressed (22, 23), we investigated the effects of VSMC-derived CO on hypoxia-induced cell growth and monitored E2F gene expression as an indicator of cell cycle progression. We report that CO modifies the cellular responses to hypoxia by inhibiting VSMC proliferation and suppressing E2F-1 gene expression and protein production leading to decreased mRNA levels of c-myc, a target gene of E2F-1 action. In addition, CO inhibited E2F-1 expression and the corresponding mitogenic response of VSMC to growth factors such as ET-1 via a cGMP-dependent pathway. These actions implicate CO as a regulator of not only vascular tone, but also of VSMC growth.


EXPERIMENTAL PROCEDURES

Cell Culture

Primary cultures of rat aortic VSMC were grown in Dulbecco's modified Eagle's medium (JRH Biosciences, Lenexa, KS) with 10% newborn calf serum, were passed every 3 to 4 days as described previously (1, 3) and used between passages 5 and 10. When they reached 60-70% confluency, media were changed to Dulbecco's modified Eagle's medium with 0.2% newborn calf serum, and cultured for an additional 48 h prior to exposure to hypoxia. Various reagents were added immediately prior to hypoxic exposure. The hypoxic gas mixture (95% N2, 5% CO2) was preanalyzed and infused into airtight incubators with in-flow and out-flow valves (Billups-Rothenberg, Del Mar, CA) at a flow rate of 3 liters/min for 15 min as previously to attain a Po2 of 18-20 mm Hg (24). For the CO experiments, a preanalyzed gas mixture (5% CO, 5% CO2, room air) was infused at the same flow rate.

Cell Replication

Cell replication was assessed by counting cell number. After various incubation periods, cells were washed twice with ice-cold PBS, harvested, and centrifuged. Cell pellets were resuspended in ice-cold PBS and counted with a Coulter counter (Coulter Corp., Hialeah, FL). Growth rate was determined by plotting cell number over time in semilog scale and extrapolating the slope.

RNA Analysis

Total cellular RNA was prepared by guanidinium isothiocyanate extraction from VSMC exposed to normoxia or hypoxia in the presence or absence of reagents for various periods. Total RNA (15 µg/lane) was separated by electrophoresis on 1% agarose gels containing formaldehyde and transferred to nitrocellulose membranes by blotting. The filters were hybridized with cDNA probes specific for the rat c-myc (generous gift from Dr. Peter Brecher, Boston University Medical Center) and the rat E2F-1 and E2F-5 genes (19). The cDNA fragments were labeled with [alpha -32P]dCTP using a standard random-primed reaction to a specific activity of 1-2 × 109 cpm/µg. The membranes were hybridized for 2 h at 68 °C in QuikHyb solution (Stratagene, La Jolla, CA) with 2 × 106 cpm/ml of probe, and washed twice in 2 × SSC containing 0.1% SDS at 60 °C for 30 min, and were then exposed to film (X-Omat AR; Eastman Kodak, Rochester, NY) with intensifying screens at -80 °C. The membranes were subsequently stripped and rehybridized with a 32P-labeled mouse beta -actin probe. For quantitation, we scanned autoradiographs with a laser densitometer (Ultroscan XL; LKB Instruments, Inc., Bromma, Sweden) running the Gel Scan XL software package (Pharmacia LKB Biotechnology, Piscataway, NJ).

Nuclear Run-on Analysis

VSMC were serum-deprived for 48 h and then placed in 10% serum-containing media in the absence or presence of 50 µM hemoglobin (Hb) prior to exposure to hypoxia for 12 h. Nuclei then were isolated and in vitro transcription was performed as described previously (25). Hybridization to denatured probes (1 µg) slot-blotted on nitrocellulose filters was performed at 40 °C for 4 days in the presence of 50% formamide. cDNA for rat E2F-1, rat HO-1 (3), and beta -actin were used as probes.

cGMP Accumulation in VSMC

After exposure to hypoxia or normoxia for 12 h, cGMP concentration was determined in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (1 mM), which was added to the plates for the last 20 min of incubation. Media were aspirated, cells washed with ice-cold phosphate-buffered saline and solubilized with cold 65% ethanol. The cellular lysates were clarified by centrifugation at 2000 × g for 15 min at 4 °C. The supernatants were evaporated at 60 °C in a vacuum oven and maintained at -80 °C until assay. cGMP concentrations were determined by radioimmunoassay (Amersham, Arlington Heights, IL) per manufacturer's instructions and normalized to protein content as measured by a dye-binding assay (Bio-Rad) using bovine serum albumin as the standard.

Nuclear Extract Preparation and Western Analysis

VSMC were grown to 80% confluency and exposed to hypoxia or normoxia for 12 h in the presence or absence of Hb (50 µM) in fresh, serum-replete media. Cells were trypsinized, washed twice with PBS, and nuclear extracts were prepared as described previously (14). Briefly, cells were resuspended in 5 packed cell volumes of buffer A (10 µM Tris-HCl (pH 7.6), 1.5 µM MgCl2, 10 µM KCl) with 2 µM dithiothreitol and proteinase inhibitors. Cell membranes were lysed using a Dounce homogenizer and after centrifugation, the nuclear pellet was lysed in buffer C (0.42 M KCl, 20 µM Tris-HCl (pH 7.6), 20% glycerol, 1.5 µM MgCl2). Nuclear proteins were isolated in the supernatant after centrifugation at 15,000 × g for 30 min. 30 µg of nuclear protein per sample were fractionated in 12% SDS-polyacrylamide gel electrophoresis gel followed by transfer to nitrocellulose membrane. Nonspecific binding was blocked with 5% nonfat dry milk in PBS-T (0.05% Tween 20 in PBS) for 1 h. The blot was then incubated with antimouse monoclonal E2F-1 antibody (Transduction Laboratories, Lexington, KY) at a dilution of 1:100 for 16 h at 4 °C. After washing with PBS-T, the membrane was exposed to anti-mouse whole immunoglobin horseradish peroxidase-conjugated antibody (Amersham) at a ratio of 1:2500 for 3 h at 4 °C. Immunoreactivity was detected using the standard enhanced chemiluminescence method (Amersham) according to the manufacturer's manual.

Reagents

Tin protoporphyrin IX (SnPP-9), zinc protoporphyrin-IX (ZnPP-9), and cobalt protoporphyrin IX were purchased from Porphyrin Products, Inc. (Logan, UT). All other reagents used were obtained from Sigma, unless otherwise specified. Hb was prepared by treatment with excess reducing agent (26) to prevent oxidant-stress injury to the cells (27).

Data Analysis

Significant differences were determined by one-way ANOVA and p < 0.05 was considered statistically significant.


RESULTS

Hypoxia Enhances the Response of VSMC to the Mitogen ET-1

We exposed VSMC to hypoxia or normoxia for various periods of time and examined their growth in the two oxygen environments. Cultures were incubated in the presence of serum (10%) or ET-1 (10 nM) and cell number was compared with that of parallel cultures without serum or mitogens. ET-1 was used as the mitogen because its production is increased by hypoxia in endothelial cells (24) and was shown to stimulate proliferation of co-cultured VSMC (11). We found that hypoxic VSMC had a more pronounced proliferative response to ET-1 (Fig. 1) or to serum (not shown) than their normoxic counterparts. Similar findings have been reported for fibroblasts, which were shown to proliferate at higher rates in response to serum and growth factors under hypoxic conditions (28). In the absence of serum or exogenous growth factors, VSMC number did not increase significantly under hypoxia and increased only modestly under normoxia (Fig. 1).


Fig. 1. A, hypoxia regulates the proliferation rate of VSMC. Cell number was determined over time. VSMC cultures were serum-deprived (0.2% serum) for 48 h prior to exposure to hypoxia or normoxia at time 0. ET-1 (10 nM) was added to parallel cultures under normoxia or hypoxia as indicated. The experiment was performed three times and each point was repeated six times. Values are shown as mean ± S.E. (n = 6). *, p < 0.05; ***, p < 0.001 versus baseline cell number.

[View Larger Version of this Image (16K GIF file)]


CO Decreases the Proliferative Response of VSMC to ET-1

We have reported that VSMC exposed to hypoxia express significantly higher levels of HO-1 compared with cells cultured under normoxic conditions, and that this up-regulation of HO-1 activity results in a dramatic increase in CO levels in the conditioned media (3). To examine if CO modulates the proliferative response of VSMC to exogenous mitogens, we exposed cells to hypoxia in the absence of serum (basal) or in serum-free media plus exogenous ET-1 and controlled the CO levels in the cultures through various treatments (Fig. 2). The presence of hemin, a potent inducer of HO activity and CO production, did not affect VSMC proliferation under either basal or ET-1-stimulated conditions. This is not unexpected because hypoxic VSMC already produce high levels of CO (3). The HO-1 inhibitors SnPP-9 and ZnPP-9 were used to decrease endogenous CO production and Hb was used to remove CO from the culture media. Although these agents did not alter the proliferation of VSMC under normoxia (not shown), hypoxic VSMC proliferated at significantly higher rates in their presence. Significantly, inhibition of HO or removal of CO with Hb resulted in increased VSMC proliferation even in the absence of growth factors (hatched bars). In fact, although maximal proliferation was observed in cells treated with ET-1 (solid bars), modulators of CO levels had an equal or more striking relative proliferative effect on VSMC under basal conditions. To confirm that it is the gaseous molecule CO that regulates VSMC growth, we exposed serum-replete VSMC to exogenous CO under normoxic conditions and demonstrated a significant suppression of proliferation compared with that of control cultures (Fig. 3). This anti-proliferative effect was negated by the presence of Hb, a potent scavenger of CO, while Hb by itself had no effect on VSMC growth under control conditions. We also treated normoxic cultures, grown in the presence of serum or ET-1, with hemin to stimulate CO production. VSMC proliferation in treated cultures was significantly reduced to 50% of the controls, as judged by cell number counts at 48 h (data not shown). The above experiments strongly suggest that CO levels can play a significant role in modulating VSMC growth under both normoxic and hypoxic conditions. Significantly, in the latter case, CO can attenuate the hypoxia-induced hyper-responsiveness of VSMC to mitogens.


Fig. 2. Endogenous CO levels regulate VSMC proliferation under hypoxia. VSMC number is determined 48 h after exposure to hypoxia in serum-deprived cells (basal, hatched bars) and in cells cultured in the presence of 10 nM ET-1 (solid bars). Cultures were treated with the HO-1 inhibitors SnPP-9 (100 µM) and ZnPP-9 (10 µM), Hb (50 µM), or the HO-1 inducer, hemin (He) (5 µM), to modulate the endogenous CO levels. The experiment was repeated three times in quadruplicate. Mean values ± S.E. (n = 4) are shown. **, p < 0.01; ***, p < 0.001 versus control numbers at time 0.

[View Larger Version of this Image (25K GIF file)]



Fig. 3. Exogenous CO decreases VSMC proliferation. Serum-deprived VSMC cultures were exposed to 21% O2 (control) or 5% CO environments in the presence or absence of Hb (50 µM) and cell number was determined at the times indicated. The experiment was repeated three times in quadruplicate. n = 4, **, p < 0.01; ***, p < 0.001 versus control.

[View Larger Version of this Image (16K GIF file)]


CO Regulates the Expression of Cell Cycle-specific Transcription Factor E2F-1

To further characterize the effects of CO on VSMC proliferation, we examined the expression of the transcription factor E2F-1, a key regulator of cell cycle control (17, 18). Treatment of normoxic VSMC with ET-1 resulted in a roughly 4-fold rise in E2F-1 mRNA levels after 24 h with return to baseline levels by 48 h (Fig. 4A, lanes 6 and 8, respectively). In contrast, under hypoxia, E2F-1 mRNA increased 3-fold by 12 h, peaked to about 4-fold by 24 h, and was again significantly elevated 3-fold above baseline levels at 48 h (lanes 5, 7, and 9, respectively). This effect was specific for E2F-1, as the mRNA levels of E2F-5, another member of the E2F family of cell cycle regulators as well as beta -actin mRNA levels were unaffected by neither hypoxia nor ET-1. Hypoxia thus results in a more rapid and sustained elevation of VSMC E2F-1 levels upon exposure to ET-1, in good correlation with the enhanced mitogenic response of hypoxic VSMC to this growth factor (Fig. 1).


Fig. 4. Hypoxia regulates E2F-1 mRNA levels. A, response to the growth factor, ET-1. Northern blot analysis of total RNA isolated from VSMC treated with ET-1 (10 nM) and exposed to hypoxia or normoxia for the time indicated. beta -Actin mRNA is shown below and relative E2F-1 and E2F-5 mRNA levels normalized to actin are indicated in numbers below the bands. B, hypoxia suppresses E2F-1 mRNA in the absence of mitogens. Cells were cultured for the indicated time in the same oxygen environments as in A but without ET-1. Northern analysis was performed as above. In both A and B, the panels shown are representative of independent experiments performed at least twice.

[View Larger Version of this Image (46K GIF file)]


Fig. 4B shows the effect of hypoxia on E2F-1 mRNA levels in VSMC cultured in the absence of serum or growth factors. In parallel with the observed suppression of VSMC growth under these conditions (see Fig. 1), E2F-1 mRNA levels were reduced by roughly 50% in a hypoxic environment (lanes 3, 5, and 7) compared with normoxia (lanes 1, 2, 4, and 6). Again, E2F-5 and beta -actin mRNA levels were unaffected by these treatments.

The effect of CO on E2F-1 mRNA levels is shown in Fig. 5. As above, when cells were treated with the mitogen ET-1, hypoxia significantly increased E2F-1 mRNA levels (Fig. 5A, lanes 1 and 2). However, E2F-1 mRNA was hyper-induced by hypoxia when CO levels were decreased by SnPP-9, ZnPP-9, or Hb (lanes 4, 6, and 8, respectively) but not when CO release was stimulated with hemin (lane 10). Again, this effect was specific for E2F-1 as mRNA levels of E2F-5 were unaffected by the presence or absence of CO (middle panel). Therefore, CO antagonizes the growth response of VSMC to the mitogen ET-1 (Fig. 2) and also suppresses the cell cycle-specific transcription factor E2F-1. In the absence of growth factors, hypoxia suppressed E2F-1 mRNA levels (Fig. 5B, lane 2) but inhibition of CO reversed this hypoxic effect (lanes 4, 6, and 8). Conversely, increasing CO with the addition of hemin did not prevent the suppression of E2F-1 by hypoxia (compare lanes 9 and 10). CO, therefore, modulates VSMC growth and cell-cycle progression (as assessed by E2F-1 expression) irrespective of exogenously added growth factors.


Fig. 5. Inhibitors of CO increase E2F-1 mRNA levels under hypoxia. A, effect of ET-1. Northern blot analysis of total RNA extracted from VSMC treated with ET-1 (10 nM) and exposed to normoxia or hypoxia for 12 h with no additions (lanes 1 and 2), in the presence of SnPP-9 (lanes 3 and 4), Hb (lanes 5 and 6), ZnPP-9 (lanes 7 and 8), or hemin (He) (lanes 9 and 10) in the same concentrations as in Fig. 2. E2F-5 mRNA levels are shown in the middle panel. The same blot was hybridized with the beta -actin probe as described previously. Relative mRNA levels (normalized to beta -actin mRNA) are indicated in numbers below the bands. Data are representative of two separate experiments. B, effect of CO in the absence of growth factors. E2F-1 mRNA levels are shown in response to the same agents as in A but in the absence of ET-1. The experiment was repeated twice.

[View Larger Version of this Image (59K GIF file)]


The effect of CO on the transcriptional rate of the E2F-1 gene was determined by nuclear run-on analysis (Fig. 6A). Cells were exposed to hypoxia in the presence or absence of the CO scavenger, Hb for 12 h. Transcriptional rates of HO-1, a gene dramatically regulated by endogenous levels of CO as we have previously reported (3), and beta -actin were analyzed for comparison. Under hypoxia, removal of CO from the cultures with Hb markedly induced the transcriptional rate of both the E2F-1 and HO-1 genes (4- and 10-fold, respectively, as assessed by densitometry), whereas beta -actin transcription was unaffected.


Fig. 6. A, endogenous CO regulates E2F-1 gene transcription. VSMC were exposed to hypoxia (H) or hypoxia plus 50 µM Hb (H+Hb) for 12 h in the presence of 10% serum. Nuclei were isolated and transcription was allowed to resume in vitro in the presence of [alpha -32P]UTP. Equal amounts of 32P-labeled, in vitro transcribed RNA were hybridized to denatured cDNA for the E2F-1, HO-1, and beta -actin genes, previously immobilized on nitrocellulose filters. Shown is a representative autoradiogram of two independent experiments. B, endogenous CO regulates E2F-1 protein levels in hypoxic VSMC. VSMC were treated as in A and nuclear proteins isolated. 30 µg of protein/lane were electrophoresed and Western analysis performed using anti-E2F-1 antibody. This figure is representative of two independent experiments.

[View Larger Version of this Image (32K GIF file)]


To determine if the changes in E2F-1 gene expression and mRNA levels result in changes of E2F-1 protein levels in VSMC, nuclear proteins were isolated and Western analysis was performed (Fig. 6B). Using a monoclonal antibody to E2F-1, 2-fold greater amounts of E2F-1 were detected under hypoxic conditions for 12 h compared to normoxic controls (lane 4 versus lane 2), with a more striking 4-fold increase above baseline noted upon removal of CO from the cultures (lane 5 versus lane 2).

E2F-1 is known to regulate the transcription of other cell-cycle specific genes including c-myc (18). To examine whether the increased E2F-1 expression upon removal of CO from the cultures results in increased expression of E2F-1 target genes, we monitored c-myc mRNA levels. In parallel with enhanced VSMC proliferation and E2F-1 mRNA expression, we found a 2-fold increase in c-myc mRNA levels when cells were exposed to hypoxia for 12 h and CO was removed from the cultures with Hb (results not shown). Combined with the above findings, these results point to CO as the modulator of genes encoding growth factors and transcription factors critical to cell cycle progression and cell proliferation.

cGMP Mediates the Suppression of E2F-1 by CO

Exogenous CO is known to activate guanylyl cyclase and elevate cGMP levels (29, 30). We have previously reported that the CO produced by VSMC under hypoxia increases cGMP content in both VSMC (3) as well as adjacent endothelial cells (11). As previously, we found a significant 9-fold rise in cGMP levels in VSMC exposed to hypoxia for 12 h (23 pmol/mg of cell protein) compared with normoxic controls (2.5 pmol/mg of cell protein) (Fig. 7). This rise in cGMP was inhibited by SnPP-9 (3) and by Hb but was unaffected by inhibitors of NO synthesis (Fig. 7). Therefore, the rise in cGMP detected in VSMC under hypoxia is due to the activity of CO and not NO.


Fig. 7. Hypoxia increases cGMP levels in VSMC via CO. cGMP content (picomole per mg of cell protein, mean ± S.E.) are shown for four separate experiments performed in duplicate after exposure of VSMC to hypoxia or normoxia in the presence of 10 nM ET-1 for 12 h. Nomega -nitro-L-arginine (2.5 mM) or Hb were added as indicated. **, p < 0.001 versus hypoxia without Hb.

[View Larger Version of this Image (18K GIF file)]



Fig. 8. cGMP mediates the CO effects on E2F-1 mRNA and VSMC growth. A, Northern analysis of total RNA extracted from VSMC exposed to hypoxia for 12 h in low serum (basal) or in the presence of 10 nM ET-1 and 8-bromo-cGMP (1 mM) or methylene blue (10 µM). The same blot was hybridized with the beta -actin probe as shown. Relative mRNA levels (normalized to beta -actin mRNA) are indicated in numbers below the bands. Data are representative of two independent experiments. B, exogenous cGMP inhibits VSMC growth. VSMC number was determined at times indicated in cultures treated with 8-bromo-cGMP (1 mM) in the presence of ET-1 (10 nM) under normoxic conditions. n = 4; ***, p < 0.001 versus control.

[View Larger Version of this Image (26K GIF file)]


To investigate if the cGMP pathway is involved in the suppression of E2F-1 expression by CO, we exposed VSMC to hypoxia for 12 h in the presence of 8-bromo-cGMP or methylene blue at concentrations previously reported to inhibit guanylyl cyclase activity (31). As shown in Fig. 8A, 8-bromo-cGMP lowered E2F-1 mRNA levels both in the absence (to 30% of control) or presence of ET-1 (to 16% of control) (compare lanes 2 and 5 with lanes 1 and 4, respectively). Conversely, when guanylyl cyclase was inhibited with methylene blue, E2F-1 mRNA was markedly induced above control levels in the absence or presence of ET-1. E2F-5 mRNA (not shown) and beta -actin mRNA levels (Fig. 8A, lower panel) were unaffected by these agents suggesting that the effects of the cGMP analogue and methylene blue are specific for E2F-1. Treatment of cells with ODQ, a more specific inhibitor of guanylyl cyclase resulted in similar induction of E2F-1 mRNA as with methylene blue (data not shown). cGMP may thus be an important messenger in the CO pathway that regulates E2F-1 expression and ultimately proliferation under basal and mitogen-stimulated conditions. Indeed, treatment of VSMC with 8-bromo-cGMP dramatically reduced their growth in response to ET-1 (Fig. 8B) as was found to be the case with both nemin and exogenous CO treatment (Figs. 2 and 3, respectively).


DISCUSSION

Proliferation of vascular cells plays an essential role in the pathogenesis of cardiovascular diseases such as atherosclerosis, intimal hyperplasia, and pulmonary hypertension. Hypoxia, often an underlying factor in these diseases, is a strong stimulus for vascular cell proliferation. Hypoxia has been shown to increase the expression of the growth factors ET-1 (24) and PDGF-B (25) while decreasing the production of NO (22, 23), an inhibitor of VSMC growth, thus predisposing to excess smooth muscle cell proliferation in the vasculature.

We report here that cultured VSMC exposed to hypoxic conditions proliferated at significantly increased rates in response to the mitogen ET-1 compared with normoxic cells. These findings are in agreement with a previous study showing an increased proliferative response of fibroblasts to serum and growth factors under low oxygen conditions (28). In addition, we report that hypoxia specifically increased mRNA and protein levels of E2F-1, a transcription factor involved in the orderly progression of cells from the G1 to the S phase but it did not affect the expression of E2F-5, another member of the E2F family, which presumably controls a checkpoint in earlier phases of the cell cycle. In the absence of growth factors, VSMC proliferation rate remained low under hypoxia and similarly, E2F-1 mRNA levels remained suppressed with continued hypoxia as cells were growth arrested. Although the cascade of events mediating the hypoxic response has yet to be characterized, our results indicate that E2F-1 plays a critical role in this pathway.

VSMC were recently shown to produce CO under conditions of hypoxia (3) which inhibited the production of ET-1 and PDGF-B in adjacent endothelial cells in a paracrine manner (11). We hypothesized that VSMC-derived CO may also have endothelial-independent effects on VSMC growth and in the current study designed experiments to test this hypothesis. We approached this question at multiple levels by modulating endogenous CO production or by administering exogenous CO as well as examining potential intracellular signaling molecules that could mediate the actions of CO.

VSMC were treated with ZnPP-9 or SnPP-9 to inhibit CO production or with Hb to scavenge CO from the media. When CO was removed from the cultures with these treatments under hypoxic conditions, VSMC demonstrated even a more pronounced growth response to the mitogen ET-1. These agents had no effect on VSMC growth under normoxic conditions when CO levels are low to absent (3). Since metalloporphyrins are not only strong inhibitors of HO activity but have also been reported to regulate the enzymatic action of nitric-oxide synthase and guanylyl cyclase (10, 32, 33), we have tested multiple doses of SnPP-9, ZnPP-9, and cobalt protoporphyrin IX to regulate HO activity (11). Furthermore, we used hemin as well as exogenous CO to confirm that it is CO which is responsible for the regulation of VSMC growth. Our findings demonstrate that whereas inhibitors of CO hyper-stimulated VSMC growth under hypoxic conditions, exogenous CO significantly reduced cell growth even under normoxia.

Inhibitors of CO synthesis amplified the proliferative response of VSMC to the mitogen ET-1 and also increased E2F-1 mRNA levels and gene transcription 4-fold above baseline. This effect was specific for the E2F-1 gene as E2F-5 expression was unaffected by CO levels. The importance of E2F-1 in the regulation of VSMC growth was suggested in a recent study by Morishita et al. (34) who used an oligonucleotide that contained the E2F site to inhibit VSMC proliferation both in vitro and in vivo, preventing neointimal formation in a carotid injury model. Since E2F-1 activity is critical for the coordinated expression of multiple S-phase genes, its modulation can alter a cell's ability to respond to growth factors (35). Indeed, our findings indicate that CO is a potent regulator of E2F-1 and at least one of its target genes (i.e. c-myc). Although we cannot rule out additional effects of CO on cell cycle control pathways, our studies suggest that E2F-1 may be a downstream target of the pathway through which CO regulates VSMC proliferation.

CO shares some of the properties of NO. Both are gas molecules normally produced in the body and are capable of activating guanylyl cyclase leading to increased cGMP production. Exogenous NO has been reported to inhibit VSMC growth partly through elevating cGMP levels (8). However, under hypoxia, NO synthesis is suppressed in endothelial cells resulting in depressed cGMP levels in both endothelial cells and adjacent VSMC (22). Furthermore, transcripts of nitric-oxide synthase were not detectable in VSMC in the absence of cytokine stimulation (3, 36) and treatment of VSMC with nitric-oxide synthase inhibitors did not eliminate cGMP accumulation under either normoxia or hypoxia (11) (see also Fig. 7). In this study we showed that it is the endogenously-derived CO in hypoxic VSMC that increases cGMP levels and demonstrated that the expression of E2F-1 is inversely related to cGMP levels. We therefore propose that it is the VSMC-derived CO and not NO, that regulates E2F-1 gene expression and VSMC growth via a cGMP-dependent pathway in response to hypoxia.

The increased production of ET-1 and PDGF-B by hypoxic endothelial cells combined with the suppression of endothelial nitric-oxide synthase would be expected to accelerate VSMC growth. On the other hand, a counter-proliferative system is also in effect under hypoxia. Using a co-culture system of endothelial cells and VSMC, we reported that VSMC-derived CO suppressed the hypoxic increases in ET-1 and PDGF-B production by endothelial cells in a paracrine manner (11). In this report, we showed that CO has additional effects on VSMC proliferation that are endothelial cell-independent. Therefore, CO has both direct and indirect antiproliferative effects on VSMC growth. In this manner, CO may represent the body's adaptive responses to hypoxia with both vasoactive and antiproliferative effects both of which are partly mediated by cGMP. We propose that CO, by antagonizing the proliferative effects of hypoxia on VSMC growth, may limit the cellular hyperplasia within the blood vessel wall, thus potentially decreasing the severity of cardiovascular disorders such as atherosclerosis and pulmonary hypertension.


FOOTNOTES

*   This work was supported by the American Heart Association (to S. K.) and National Institute of Health Grants GM44520 (to S. A. M.), R01 HL55454 (to S. K.), and SCOR 1P50HL46491 (to S. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: Joint Program in Neonatology, Children's Hospital, 300 Longwood Ave., Enders 9, Boston, MA 02115-5737. Tel.: 617-355-7383; Fax: 617-355-7677; E-mail: kourembanas{at}a1.tch.harvard.edu.
1   The abbreviations used are: VSMC, vascular smooth muscle cells; HO-1, heme oxygenase-1; CO, carbon monoxide; NO, nitric oxide; ET-1, endothelin-1; PDGF-B, platelet-derived growth factor-B; Hb, hemoglobin; SnPP-9, tin protoporphyrin IX; ZnPP-9, zinc protoporphyrin IX; PBS, phosphate-buffered saline.

ACKNOWLEDGEMENTS

We thank Drs. Mu-En Lee and Mark Perrella for critical review of the manuscript and Kelly Ames and Amy Elias for expert assistance in its preparation.


REFERENCES

  1. Liu, Y., Cox, S. R., Morita, T., and Kourembanas, S. (1995) Circ. Res. 77, 638-643 [Abstract/Free Full Text]
  2. Wang, G. L., Jiang, B.-H., Rue, E. A., and Semenza, G. L. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5510-5514 [Abstract/Free Full Text]
  3. Morita, T., Perrella, M. A., Lee, M.-E., and Kourembanas, S. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1475-1479 [Abstract/Free Full Text]
  4. Cook, M. N., Nakatsu, K., Marks, G. S., McLaughlin, B. E., Vreman, H. J., Stevenson, D. K., and Brien, J. F. (1995) Can. J. Physiol. Pharmacol. 73, 515-518 [Medline] [Order article via Infotrieve]
  5. Maines, M. D., Trakshel, G. M., and Kutty, R. K. (1986) J. Biol. Chem. 261, 411-419 [Abstract/Free Full Text]
  6. Schacter, B. A. (1988) Semin. Hematol. 25, 349-369 [Medline] [Order article via Infotrieve]
  7. Jenkins, D. C., Charles, I. G., Thomsen, L. L., Moss, D. W., Holmes, L. S., Baylis, S. A., Rhodes, P., Westmore, K., Emson, P. C., and Moncada, S. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4392-4396 [Abstract/Free Full Text]
  8. Garg, U. C., and Hassid, A. (1989) J. Clin. Invest. 83, 1774-1777
  9. Verma, A., Hirsch, D. J., Glatt, C. E., Ronnett, G. V., and Snyder, S. H. (1993) Science 259, 381-384 [Abstract/Free Full Text]
  10. Zakhary, R., Gaine, S. P., Dinerman, J. L., Ruat, M., Flavahan, N. A., and Snyder, S. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 795-798 [Abstract/Free Full Text]
  11. Morita, T., and Kourembanas, S. (1995) J. Clin. Invest. 96, 2676-2682
  12. Semenza, G. L., Roth, P. H., Fang, H.-M., and Wang, G. L. (1994) J. Biol. Chem. 269, 23757-23763 [Abstract/Free Full Text]
  13. Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. L. (1996) Mol. Cell. Biol. 19, 4604-46013
  14. Wang, G. L., and Semenza, G. L. (1995) J. Biol. Chem. 270, 1230-1237 [Abstract/Free Full Text]
  15. Nevins, J. R. (1992) Nature 358, 375-376 [CrossRef][Medline] [Order article via Infotrieve]
  16. Slansky, J. E., and Farnham, P. J. (1996) Curr. Top. Microbiol. Immunol. 208, 1-30 [Medline] [Order article via Infotrieve]
  17. Li, Y., Slansky, J. E., Myers, D. J., Drinkwater, N. R., Kaelin, W. G., and Farnham, P. J. (1994) Mol. Cell. Biol. 14, 1861-1869 [Abstract/Free Full Text]
  18. DeGregori, J., Kowalik, T., and Nevins, J. R. (1995) Mol. Cell. Biol. 15, 4215-4224 [Abstract]
  19. Itoh, A., Levinson, S. F., Morita, T., Kourembanas, S., Brody, J. S., and Mitsialis, S. A. (1995) Cell. & Mol. Biol. Res. 41, 147-154 [Medline] [Order article via Infotrieve]
  20. Hijmans, E. M., Voorhoeve, P. M., Beijersbergen, R. L., van't Veer, L. J., and Bernards, R. (1995) Mol. Cell. Biol. 15, 3082-3089 [Abstract]
  21. Sardet, C., Vidal, M., Cobrinik, D., Geng, Y., Onufryk, C., Chen, A., and Weinberg, R. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2403-2407 [Abstract/Free Full Text]
  22. McQuillan, L. P., Leung, G. K., Marsden, P. A., Kostyk, S. K., and Kourembanas, S. (1994) Am. J. Physiol. 267, H1921-H1927 [Abstract/Free Full Text]
  23. Liao, J. K., Zulueta, J. J., Yu, F.-S., Peng, H.-B., Cote, C. G., and Hassoun, P. M. (1995) J. Clin. Invest. 96, 2661-2666
  24. Kourembanas, S., Marsden, P. A., McQuillan, L. P., and Faller, D. V. (1991) J. Clin. Invest. 88, 1054-1057
  25. Kourembanas, S., Hannan, R. L., and Faller, D. V. (1990) J. Clin. Invest. 86, 670-674
  26. Martin, W., Villani, G. M., Jothianandan, D., and Furchgott, R. F. (1985) J. Pharmacol. Exp. Ther. 232, 708-716 [Abstract/Free Full Text]
  27. Abraham, N. G., Lavrovsky, Y., Schwartzman, M. L., Stoltz, R. A., Levere, R. D., Gerritsen, M. E., Shibahara, S., and Kappas, A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 6798-6802 [Abstract/Free Full Text]
  28. Storch, T. G., and Talley, G. D. (1988) Exp. Cell Res. 175, 317-325 [CrossRef][Medline] [Order article via Infotrieve]
  29. Ramos, K. S., Lin, H., and McGrath, J. J. (1989) Biochem. Pharmacol. 38, 1368-1370 [CrossRef][Medline] [Order article via Infotrieve]
  30. Brune, B., and Ullrich, V. (1987) Mol. Pharmacol. 32, 497-504 [Abstract]
  31. Boulanger, C., and Luscher, T. F. (1990) J. Clin. Invest. 85, 587-590
  32. Ignarro, L. J., Wood, K. S., and Wolin, M. S. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 2870-2873 [Abstract/Free Full Text]
  33. Ignarro, L. J., Ballot, B., and Wood, K. S. (1984) J. Biol. Chem. 259, 6201-6207 [Abstract/Free Full Text]
  34. Morishita, R., Gibbons, G. H., Horiuchi, M., Ellison, K. E., Nakajima, M., Zhang, L., Kaneda, Y., Ogihara, T., and Dzau, V. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5855-5859 [Abstract/Free Full Text]
  35. Schwarz, J. K., Bassing, C. H., Kovesdi, I., Datto, M. B., Blazing, M., George, S., Wang, X.-F., and Nevins, J. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 483-487 [Abstract/Free Full Text]
  36. Perrella, M. A., Yoshizumi, M., Fen, Z., Tsai, J.-C., Hsieh, C.-M., Kourembanas, S., and Lee, M.-E. (1994) J. Biol. Chem. 269, 14595-14600 [Abstract/Free Full Text]

Volume 272, Number 52, Issue of December 26, 1997 pp. 32804-32809
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Nutr.Home page
A. M. Kivela, E. Kansanen, H.-K. Jyrkkanen, T. Nurmi, S. Yla-Herttuala, and A.-L. Levonen
Enterolactone Induces Heme Oxygenase-1 Expression through Nuclear Factor-E2-Related Factor 2 Activation in Endothelial Cells
J. Nutr., July 1, 2008; 138(7): 1263 - 1268.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
N. G. Abraham and A. Kappas
Pharmacological and Clinical Aspects of Heme Oxygenase
Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Ito, T. Okada, H. Miyashita, T. Nomoto, M. Nonaka-Sarukawa, R. Uchibori, Y. Maeda, M. Urabe, H. Mizukami, A. Kume, et al.
Interleukin-10 Expression Mediated by an Adeno-Associated Virus Vector Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
Circ. Res., September 28, 2007; 101(7): 734 - 741.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
G. Kitsios and E. Zintzaras
Genetic Variation associated with Ischemic Heart Failure: A HuGE Review and Meta-Analysis
Am. J. Epidemiol., September 15, 2007; 166(6): 619 - 633.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. Tiroch, W. Koch, N. von Beckerath, A. Kastrati, and A. Schomig
Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting
Eur. Heart J., April 2, 2007; 28(8): 968 - 973.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
L. E. Fredenburgh, M. A. Perrella, and S. A. Mitsialis
The Role of Heme Oxygenase-1 in Pulmonary Disease
Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 158 - 165.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. W. Ryter, D. Morse, and A. M. K. Choi
Carbon Monoxide and Bilirubin: Potential Therapies for Pulmonary/Vascular Injury and Disease
Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 175 - 182.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Wang, Y. Wang, H. P. Kim, K. Nakahira, S. W. Ryter, and A. M. K. Choi
Carbon Monoxide Protects against Hyperoxia-induced Endothelial Cell Apoptosis by Inhibiting Reactive Oxygen Species Formation
J. Biol. Chem., January 19, 2007; 282(3): 1718 - 1726.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Stocker and M. A. Perrella
Heme Oxygenase-1: A Novel Drug Target for Atherosclerotic Diseases?
Circulation, November 14, 2006; 114(20): 2178 - 2189.
[Full Text] [PDF]


Home page
J. Exp. Med.Home page
B. S. Zuckerbraun, B. Y. Chin, B. Wegiel, T. R. Billiar, E. Czsimadia, J. Rao, L. Shimoda, E. Ifedigbo, S. Kanno, and L. E. Otterbein
Carbon monoxide reverses established pulmonary hypertension
J. Exp. Med., September 4, 2006; 203(9): 2109 - 2119.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
S. W. Ryter, J. Alam, and A. M. K. Choi
Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications
Physiol Rev, April 1, 2006; 86(2): 583 - 650.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Mishra, T. Fujita, V. N. Lama, D. Nam, H. Liao, M. Okada, K. Minamoto, Y. Yoshikawa, H. Harada, and D. J. Pinsky
Carbon monoxide rescues ischemic lungs by interrupting MAPK-driven expression of early growth response 1 gene and its downstream target genes
PNAS, March 28, 2006; 103(13): 5191 - 5196.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
C. W. Leffler, H. Parfenova, J. H. Jaggar, and R. Wang
Carbon monoxide and hydrogen sulfide: gaseous messengers in cerebrovascular circulation
J Appl Physiol, March 1, 2006; 100(3): 1065 - 1076.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
K. A. Kirkby and C. A. Adin
Products of heme oxygenase and their potential therapeutic applications
Am J Physiol Renal Physiol, March 1, 2006; 290(3): F563 - F571.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
L. Wu and R. Wang
Carbon Monoxide: Endogenous Production, Physiological Functions, and Pharmacological Applications
Pharmacol. Rev., December 1, 2005; 57(4): 585 - 630.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
D. Morse and A. M. K. Choi
Heme Oxygenase-1: From Bench to Bedside
Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 660 - 670.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Morita
Heme Oxygenase and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1786 - 1795.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
T. Gulesserian, C. Wenzel, G. Endler, R. Sunder-Plassmann, C. Marsik, C. Mannhalter, N. Iordanova, M. Gyongyosi, J. Wojta, S. Mustafa, et al.
Clinical Restenosis after Coronary Stent Implantation Is Associated with the Heme Oxygenase-1 Gene Promoter Polymorphism and the Heme Oxygenase-1 +99G/C Variant
Clin. Chem., September 1, 2005; 51(9): 1661 - 1665.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. P. Kim, X. Wang, A. Nakao, S. I. Kim, N. Murase, M. E. Choi, S. W. Ryter, and A. M. K. Choi
Caveolin-1 expression by means of p38{beta} mitogen-activated protein kinase mediates the antiproliferative effect of carbon monoxide
PNAS, August 9, 2005; 102(32): 11319 - 11324.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Taille, J. El-Benna, S. Lanone, J. Boczkowski, and R. Motterlini
Mitochondrial Respiratory Chain and NAD(P)H Oxidase Are Targets for the Antiproliferative Effect of Carbon Monoxide in Human Airway Smooth Muscle
J. Biol. Chem., July 8, 2005; 280(27): 25350 - 25360.
[Abstract] [Full Text] [PDF]